A case of chickenpox with multiple bacterial complications requiring surgical treatment

Chickenpox is a controlled infection, even a single vaccination effectively prevents the development of severe forms (up to 98%).

Purpose — to demonstrate a case of severe chicken pox in a child aged 3.8 years with secondary infection of the skin of the right subscapular region and subcutaneous fat (phlegmon of the trunk) of streptococcal etiology.

The diagnosis of varicella was confirmed by the detection of Varicella-Zoster virus DNA by PCR from the skin. Surgical treatment was performed — opening and drainage of phlegmon, purulent-serous discharge was obtained, sowing was performed, Streptococcus pyogenes was isolated.

The child received antibiotic therapy — cefepime sulbactam, amikacin, acyclovir, infusion therapy, local treatment.

Conclusions. The given clinical case demonstrates the development of a severe bacterial complication of chicken pox, which required surgical treatment and substantiates the need for vaccination against chicken pox and its possible complications.

1. On the state of sanitary and epidemiological well-being of the population in the Russian Federation in 2020: State report. M.: Federal Service for Supervision of Consumer Rights Protection and Human Welfare, 2021:256. (In Russ.)

2. Varicella and herpes zoster vaccines: WHO position paper, June 2014. Wkly Epidemiol Rec. 2014 Jun 20; 89(25):265—87.

3. Gershon A.A. et al. In: Plotkin S.A. et al. Varicella Vaccine. 7th ed. Elsevier Saunders; 2017:1145−1180.

4. Samodova O.V., Kriеger E.A., Titova L.V. Bacterial Complications of Chickenpox in Children. Detskie Infektsii= Children's Infections. 2015; 14(3):56—60. (In Russ.) https://doi.org/10.22627/2072-8107-2015-14-3-56-60

5. Martynova G.P., Kutishcheva I.A., Evreimova S.V., Karasev A.V., Alyeva L.P., Grigoryeva N.I. Clinical and epidemiological features of chickenpox at the present stage. Infektsionnyye Bolezni=Iinfectious Diseases. 2012; 10(4):18—23. (In Russ.)

6. Heininger U., Seward J.F. Varicella. Lancet. 2006 Oct 14; 368(9544):1365—76. doi: 10.1016/S0140-6736(06)69561-5.

7. Leung J., Bialek S.R., Marin M. Trends in varicella mortality in the United States: Data from vital statistics and the national surveillance system. Hum Vaccin Immunother. 2015 Mar; 11(3):662—668. doi: 10.1080/21645515.2015.1008880

8. Abrams D., Derrick G., Penny D.J., Shinebourne E.A., Redington A.N.. Cardiac complications in children following infection with varicella zoster virus. Cardiol Young. 2001 Nov; 11(6):647—52. doi: 10.1017/s1047951101001019.

9. Baxter R., Ray P., Tran T.N., Black S., Shinefield H.R., Coplan P.M., Lewis E., Fireman B., Saddier P. Long-term effectiveness of varicella vaccine: a 14-Year, prospective cohort study. Pediatrics. 2013 May; 131(5):e1389—96. doi: 10.1542/peds.2012-3303.

10. Marin M., Marti M., Kambhampati A., Jeram S.M., Seward J.F. Global Varicella Vaccine Effectiveness: A Meta-analysis. Pediatrics. 2016; 137(3):e20153741. doi: 10.1542/peds.2015-3741.

11. Saburova O.A., Sobchak D.M., Otmakhova K.A. Study of T-cell immunity, interferogenesis, inflammatory mediators in children with Varicella zoster virus infection. Detskie Infektsii=Children's Infections. 2022; 21(1):41—44. (In Russ.) https://doi.org/10.22627/2072-8107-2022-21-1-41-44